-
Pan-RAS Inhibitor Offers Hope of Improved Pancreatic Cancer Prognosis
May 30 | Bio-IT World | A consortium of pancreatic cancer researchers sharing information in real time has shown that an oral pan-RAS inhibitor known as RMC-7977, developed by Revolution Medicines, effectively targets the common cancer-causing RAS proteins while minimally impacting normal cells—and did so across a comprehensive range of preclinical models in a series of similar experiments. More -
Ambry Genetics, PacBio Take on Rare Diseases, Regeneron Makes TOP500 List, More
May 29 | Bio-IT World | Ambry Genetics and PacBio to support the Pediatric Mendelian Genomics Research Center (MGRC) program to better understand the underlying biology of rare diseases; Recursion’s BioHive-2 was dubbed No. 35 on the latest TOP500 list of the world’s fastest supercomputers; the Catalogue of Somatic Mutations in Cancer (COSMIC) launches its 100th version; more. More -
Follow the Money: Funds for Alzheimer’s Research, CN Bio Accelerates Oncology Products, More
May 28 | Bio-IT World | Laurence Belfer gifts funds to MD Anderson Cancer Center to strengthen neurodegeneration research through the Belfer Neurodegeneration Consortium; CN Bio plans to accelerate its expanding product portfolio; more. More -
Flagship Pioneering Lessons Learned Launching Biotech Startups
May 23 | Bio-IT World | John Damask is a cloud proponent; he makes no apologies for that. And his experience has mostly been with Amazon Web Services; he is clear on that too. With those disclosures out of the way, Damask offered a “Choose Your Own Adventure”-style tour of cloud best practices and the most common startup cloud mistakes at last month’s Bio-IT World Conference & Expo, letting the audience choose the topics he dug into during the talk. More -
Reevaluating Data Platforms: The Future of Decentralized Data
May 22 | Bio-IT World | At the 2024 Bio-IT World Conference & Expo, artificial intelligence (AI) was the main topic stirring up discussions and debates, especially generative AI and its data platforms. Data platforms are crucial tools for AI models, yet there are several barriers that hinder their utilization, efficiency, and accessibility —and none of them are technical or data-related. More -
Brain Stimulation Device Could Make Precision Mental Health A Reality
May 21 | Bio-IT World | In the not-too-distant future, disorders of the brain could be treated with the same precision as heart disease and cancer. The means will be a therapeutic brain-computer interface (BCI) the size of a small blueberry for people suffering from treatment-resistant depression that uses a similar type of implant technology as Elon Musk’s Neuralink for helping paralyzed people speak. More -
Liquid Biopsy Under Development for Measuring Drug Response
May 16 | Bio-IT World | The lab of W. Andy Tao, professor of biochemistry at Purdue University, is pioneering a way to assess drug response based on metabolizing proteins found in circulating extracellular vesicles (EVs), which could serve as a surrogate of their expression level in the liver and become therapeutic targets for some cancers. More -
New Test Looks at Unique Response of MS Patients to Epstein-Barr Virus
May 15 | Bio-IT World | Significant evidence now exists implicating the Epstein-Barr virus (EBV) as a causal factor in the development of multiple sclerosis (MS), making treatment of the virus a priority. To that end, research scientists at Trinity College Dublin have developed a blood test to measure the immune response to EBV that could be used as an outcome measure in future clinical trials in people with established MS. More -
AI System For Diagnosing Rare Diseases and Solving Medical Cold Cases
May 14 | Bio-IT World | Using an artificial intelligence (AI) model that was trained on millions of variants from identified genetic disorders and incorporates the complex decision-making process of human molecular scientists, investigators at Baylor College of Medicine are on track to automate the diagnosis of an enormous number of undiagnosed conditions. More -
The Replication Crisis: How Can Open Science Improve the Scale of Reproducibility?
May 10 | Bio-IT World | For years, two of the key principles of science have been replication and the ability to produce consistent results. Yet, scientists across fields today are still grappling with challenges in ensuring the repeatability and reliability of their findings. More recently, this has been referred to as the ‘replication crisis’ or ‘reproducibility crisis’ and details the growing concerns around the lack of reproducibility in scientific studies. More
Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and
data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!
Bio-IT World’s Trends from the Trenches podcast delivers your insider’s look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. BioTeam co-founder Stan Gloss brings years of industry experience in science, data, and technology to conversations exploring what is driving data and discovery, and what’s coming next.
Listen today!
